Valuation: Lexaria Corp

Market Cap 19.02M 16.32M 15.24M 13.98M 26.29M 1.82B 26.72M 180M 70.39M 912M 71.42M 69.86M 3.01B P/E 2026 *
-2.84x
P/E 2027 * -2.48x
Enterprise Value 19.02M 16.32M 15.24M 13.98M 26.29M 1.82B 26.72M 180M 70.39M 912M 71.42M 69.86M 3.01B EV / Sales 2026 *
951x
EV / Sales 2027 * 13.6x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2024
Director of Finance/CFO 66 01/10/2024
President 55 15/04/2015
Director TitleAgeSince
Chairman 65 26/10/2006
Director/Board Member 57 14/01/2025
Director/Board Member 72 08/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
+4.46%+4.92%+82.07%+134.31% 1,141B
+0.85%+4.81%+53.77%+58.51% 659B
+2.72%+6.92%+28.99%+77.15% 470B
+0.38%+1.60%+40.28%+44.75% 366B
+0.43%+3.02%+24.54%+41.64% 302B
+0.20%+3.13%+0.82%+13.12% 254B
+4.02%+6.29%+49.67%+68.96% 239B
-0.29%-0.07%-13.76%-52.74% 207B
+2.90%+8.63%+25.11%+94.52% 183B
Average +1.33%+4.10%+32.39%+53.36% 424.55B
Weighted average by Cap. +1.14%+4.31%+46.77%+74.13%

Financials

2026 *2027 *
Net sales 20K 17.16K 16.02K 14.7K 27.64K 1.91M 28.09K 189K 74.02K 959K 75.1K 73.46K 3.17M 1.4M 1.2M 1.12M 1.03M 1.94M 134M 1.97M 13.26M 5.19M 67.26M 5.27M 5.15M 222M
Net income -6.64M -5.69M -5.32M -4.88M -9.17M -635M -9.33M -62.75M -24.57M -318M -24.93M -24.39M -1.05B -8.95M -7.67M -7.17M -6.58M -12.36M -855M -12.57M -84.56M -33.11M -429M -33.59M -32.86M -1.42B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-